Updates

Author Details

Joe Pierce

January 13, 2021January 13, 2021
Donanemab Found to Slow Cognitive, Functional Decline in Early Alzheimer’s

Donanemab (LY3002813), Eli Lilly’s experimental antibody-based immunotherapy, slowed cognitive and functional decline in patients at the earlier stages of Alzheimer’s disease, according to data ... Read more
January 11, 2021January 11, 2021
BXCL501 Led to Fast, Safe, Durable Drop in Agitation in Dementia Patients

BXCL501, BioXcel Therapeutics’ experimental therapy for the treatment of agitation associated with dementia, was found to be well-tolerated and able to rapidly and sustainably ... Read more
January 6, 2021January 6, 2021
Support for Research, Patient Care in US 2021 Budget Wins Praise

The Alzheimer’s Association and its advocacy affiliate, the Alzheimer’s Impact Movement (AIM), are lauding recent actions by lawmakers that will fund and advance multiple Alzheimer’s disease policies. ... Read more
January 4, 2021January 4, 2021
Phase 3 Trial of Diabetes Treatment in Early Alzheimer’s Patients Planned

Novo Nordisk is planning to initiate by midyear a pivotal Phase 3a trial of oral semaglutide, a diabetes treatment, in people with early Alzheimer’s disease. ... Read more
December 21, 2020December 17, 2020
Directory Connects Alzheimer’s Caregivers With Valuable Resources

“It’s that time of year / When the world falls in love / Every song you hear seems to say / Merry Christmas …” ... Read more

Subscribe to our mailing list

Get regular updates delivered to your email box.

Author Details

Joe Pierce

Thanks! Please check your email for a confirmation email.

November 8, 2017November 8, 2017

Anavex ‘Cautiously Optimistic’ After Noting Cognitive Improvement in Alzheimer’s Treatment

News

Anavex Life Sciences says its Alzheimer’s drug candidate Anavex 2-73 may have a role in treating the disease. Data from a long-term extension trial, although small, indicated that the therapy improved cognitive and functional measures in patients. According to data ... Read more

Donanemab Found to Slow Cognitive, Functional Decline in Early Alzheimer’s

BXCL501 Led to Fast, Safe, Durable Drop in Agitation in Dementia Patients

Support for Research, Patient Care in US 2021 Budget Wins Praise

Phase 3 Trial of Diabetes Treatment in Early Alzheimer’s Patients Planned

Directory Connects Alzheimer’s Caregivers With Valuable Resources

Fujirebio Seeks FDA’s Premarket Approval for Diagnostic Test

Biogen, Eisai Request Approval of Aducanumab for Alzheimer’s in Japan

Choosing Appropriate Gifts for Alzheimer’s Patients and Family Caregivers

Dosing Starts in Athira’s Phase 2 ACT-AD Trial Testing ATH-1017; Enrollment Ongoing

Cortexyme’s COR388 GAIN Trial Advances to Endpoint; Results Expected Late 2021

Finding That Conquering Spirit

Subscribe to our mailing list

Last Patient Finishes ALZT-OP1 Combo Therapy Trial; Results Expected Early 2021

Social Inequalities Found in US Counties With Highest Alzheimer’s Rates Among Blacks, Latinos

IGC Starts Phase 1 Study of Low-dose Cannabinoid in Alzheimer’s Patients

AlzeCure’s Lead Therapy Candidate Entering Phase 1 Testing in Sweden

Don’t Let Alzheimer’s Disease Steal Thanksgiving

Gum Disease Bacteria Found in Most Alzheimer’s Patients in Atuzaginstat Trial

Last Participant Finishes PEGASUS Clinical Trial, Results Expected Next Year

Finding Nursing Home Placement for a Loved One With Alzheimer’s

FDA Clears Neuraly to Begin Phase 2 Trial of NLY01 in Alzheimer’s Patients

FDA Committee Votes Do Not Support Aducanumab as Effective Treatment

National Family Caregivers Month Is a Chance to Spread Happiness

EMA Agrees to Review Biogen, Eisai Request for Aducanumab’s Approval

Awareness Month Activities Shine Spotlight on Alzheimer’s, Dementia

Infrastructure Is Needed to Support Familial Caregivers

Seth Rogen’s HFC ‘Game Show’ Raises $325K to Benefit Alzheimer’s Care

First Patient Dosed in Biomarker Study of Oral Alzheimer’s Therapy, ALZ-801

Embracing Happiness When Caring for a Loved One With Alzheimer’s

Simple Language Test May Predict Alzheimer’s Onset Years Before Symptoms Start

RetiSpec and Gentex Developing Technology to Detect Early Alzheimer’s

Caregivers Should Connect to Breast Cancer Awareness

First Patient Dosed in Phase 2 Trial of Bryostatin-1 in Long-term Use

GemVax Seeks Expanded Access for Mild Alzheimer’s for Planned GV1001 US Trial

The Reality of Death and Caregiving

Dosing Starts in Phase 2/3 Trial of Athira’s ATH-1017 for Alzheimer’s

Semorinemab Fails to Show Efficacy in Early Alzheimer’s Phase 2 Trial

Creating a Last Will and Testament to Care for a Loved One

$1.76M Grant to Support Trial of Jotrol, Form of Resveratrol, in Early Alzheimer’s

Mundane Errands Become Worthwhile Adventures With Alzheimer’s Disease

CDC Taps Alzheimer’s Association to Lead National Effort to Slash Dementia Risk

Sumifilam Lowers Levels of Multiple Biomarkers of Disease Activity, Trial Shows

Preventing Bias Against People With Alzheimer’s Disease